4
Changes in Ownership
Bicara Therapeutics Inc. Filed Acc 0002034668-25-000004
Chief Financial Officer sold 30,385 shares at an average $18.21 ($553,198)
- Chief Financial Officer acquired 30,385 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hyep Ivan Chief Financial Officer | 2025-10-06 | Option exercise 10b5-1 | +6,514 | $3.79 | $24,687 | 151,869 | D |
| Hyep Ivan Chief Financial Officer | 2025-10-06 | Sale 10b5-1 | −6,514 | $18.17 | $118,356 | 145,355 | D |
| Hyep Ivan Chief Financial Officer | 2025-10-07 | Option exercise 10b5-1 | +18,244 | $3.79 | $69,141 | 163,599 | D |
| Hyep Ivan Chief Financial Officer | 2025-10-07 | Sale 10b5-1 | −18,244 | $18.22 | $332,386 | 145,355 | D |
| Hyep Ivan Chief Financial Officer | 2025-10-08 | Option exercise 10b5-1 | +5,627 | $3.79 | $21,325 | 150,982 | D |
| Hyep Ivan Chief Financial Officer | 2025-10-08 | Sale 10b5-1 | −5,627 | $18.21 | $102,456 | 145,355 | D |
| Derivatives | |||||||
| Hyep Ivan Chief Financial Officer | 2025-10-06 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,514 | 146,870 | D | ||
| Hyep Ivan Chief Financial Officer | 2025-10-07 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,244 | 128,626 | D | ||
| Hyep Ivan Chief Financial Officer | 2025-10-08 | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,627 | 122,999 | D | ||
| Open-market sales · 30,385 sh · avg $18.21 · $553,198 | |||||||
Loading xslF345X05/wk-form4_1759959228.xml…